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mole cular weight biomole cules like pro-
teins.[25] As a result, most studies show 
only low loading capacities and since the 
MSN pores are generally too small they 
offer only weak protection against pro-
teases.[26] In addition, these inorganic 
nanoparticles are typically taken up into 
cells by endocytosis, which could be detri-
mental to sensitive cargo.
Recently, we showed cytosolic delivery 
of low molecular weight dyes/drugs into 
cells via membrane fusion of liposomes 
with cell membranes induced by a com-
plementary pair of coiled-coil (CC) lipo-
peptides (denoted CP4K4 and CP4E4, 
Scheme 1).[27–29] For this, these cholesterol–
poly(ethylene glycol)–peptide conjugates 
were inserted into the lipid bilayers (LBs) 
of both liposomes and live cells resulting 
in fusion between opposing membranes. Mechanistic studies 
revealed that coiled-coil formation between the complementary 
peptides E4/K4 drives this process.[30–32] Furthermore, liposomes 
containing the anticancer drug doxorubicin could target and 
kill modified HeLa cells in a zebrafish xenograft model using 
the same approach.[33] In this contribution we studied whether 
coiled-coil mediated membrane fusion[34,35] could be used for 
the delivery of large inorganic nanoparticles like protein encap-
sulated MSNs to cells (Figure 1a). Cytochrome-c (cytC) was 
chosen as a model protein as its cytosolic delivery activates the 
intrinsic apoptotic pathway. This allowed us to monitor the 
uptake of cytC loaded MSNs (MSNs/cytC) and the induction of 
apoptosis[36] as a measure of cytosolic activity of cytC.
2. Results and Discussions
2.1. cytC Encapsulation and Release Studies
For this study, a new type of MSNs featuring a cuboidal-like 
geometry (90 × 43 nm2) was synthesized (Figure 1b).[37] The 
nitrogen adsorption–desorption isotherms of MSNs exhib-
ited the characteristic type IV isotherms[38] with a Brunauer–
Emmett–Teller (BET) surface area of 506 m2 g−1 (Figure 1c). 
The pore size distribution was found to be 10 ± 1 nm.
cytC (geometric size 2.6 × 3.2 × 3.3 nm3) is a small redox pro-
tein that is present in the inner membrane of mitochondria and 
induces apoptosis when released into the cytosol.[39] The pore 
dimensions of MSNs are sufficiently large to accommodate 
cytC and the open disk-shaped mesostructure renders the 
encapsulation of cytC very efficient. Within less than 5 min 
more than 95% of cytochrome-c (cytC) was encapsulated into 
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1. Introduction
Intracellular protein delivery holds promise for a range of 
biomedical applications,[1] such as cancer therapy,[2,3] vaccina-
tion, and enzyme based therapeutics.[4] However, therapeutic 
proteins are susceptible to proteolysis and denaturation, 
limiting their efficacy in the body.[5,6] To solve the delivery 
problem, protein delivery systems based on for instance 
polymeric nanoparticles,[7] hydrogels,[8,9] or lipid-based nano-
particles[10,11] have been developed. Also mesoporous silica 
nanoparticles (MSNs) have been studied as carriers for a variety 
of biomolecules including anticancer drugs, oligonucleo-
tides, and proteins.[2,12–24] However, most MSNs used in drug 
delivery studies to date typically have pores with diameters up 
to 4 nm, thereby limiting their use as efficient carriers for high 
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the mesoporous silica nanoparticles (MSNs/cytC). The 
maximum cytC loading capacity of these cuboidal MSNs was 
determined to be 470 µg mg−1 MSNs (Figure 2a, black curve). 
The zeta-potential of MSNs/cytC also changed by increasing the 
concentration of cytC (Figure 2a, red curve), reaching almost 
neutrality at saturating concentrations of cytC. At cytC:MSNs 
weight ratios of 1:8 or 1:4 the encapsulation efficiency (EE%) 
was quantitative, revealing the excellent protein encapsulation 
potential of these large-pore MSNs. Compared to native cytC, 
the encapsulated cytC in the MSNs revealed a slight broadening 
of the adsorption peak in the UV–Vis spectrum, but no blue 
shift was observed, suggesting that the interaction between 
the protein and pore surface did not change the structure of 
cytC (Figure S1a, Supporting Information).[40] Since cytC has 
a positive charge at pH 7.4 its adsorption is mainly driven by 
electrostatic interactions with the negatively charged silanol 
groups on the surface of MSNs.[41,42] Therefore, we studied the 
influence of ionic strength on the release profile of cytC. At 
high ionic strength (270 × 10−3 m), 70.4% of cytC was released 
from MSNs/cytC which decreased to only 16.8% in low ionic 
strength (12 × 10−3 m) buffer revealing the electrostatic nature 
of protein binding (Figure S1, Supporting Information). Thus, 
cytC can be loaded with high efficiency into MSNs at low ionic 
strength and subsequently released at conditions of high ionic 
strength (e.g., inside cells).
However, the decreased surface charge of MSNs upon cytC 
loading as evidenced by the near neutral zeta-potential induced 
aggregation of the nanoparticles. To increase their colloidal sta-
bility MSNs/cytC were therefore decorated with a lipid bilayer. 
After introduction of a fusogenic lipid bilayer composed of 
Adv. Healthcare Mater. 2017, 6, 1700759
Scheme 1. Structures of CP4K4 and CP4E4.
Figure 1. Fusion between cells and lipid bilayer coated MSNs mediated by coiled-coil formation between CP4K4 and CP4E4. a) CytC (orange) is encap-
sulated into MSNs (green) and coated with a lipid bilayer upon mixing with liposomes (light blue) which are decorated with lipopeptide CP4E4 (red) 
resulting in MSNs/cytC@CPE-LBs. Cells pretreated with CP4K4 (dark blue) are mixed with MSNs/cytC@CPE-LBs resulting in membrane fusion and 
concomitant delivery of cytC into the cytoplasm. b) TEM image of MSNs, scale bar = 200 nm. c) Nitrogen adsorption–desorption isotherms and pore 
size distribution (inset).
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol 
(2:1:1 molar ratio)[43–45] the observed hydrodynamic diameter 
by dynamic light scattering of the nanoparticles was ≈230 nm 
(polydispersity index = 0.251) (Figure 2b). After loading the 
MSNs with cytC, the zeta-potential shifted from −28.0 to 
−11.6 mV. Application of the lipid bilayer onto the exterior sur-
face of these particles resulted in a more negative zeta-potential 
(−20.5 mV) (Figure 2c). As a result the lipid coated nanoparti-
cles were colloidal stable for at least one week. The presence 
of the lipid bilayer also reduced the premature release of cytC 
by a factor of ≈1.6 as the lipid bilayer acts as a physical bar-
rier[46] thereby retaining the protein better within the MSNs 
(Figure 2d).
2.2. Intracellular Delivery of cytC
Previously, we reported that a pair of complementary lipo-
peptides (i.e., CP4E4/CP4K4) designed to form coiled-coils 
was able to mediate the targeted fusion of membranes 
between liposomes and cells.[27,47] So far, this approach was 
used to deliver low molecular weight dyes and drugs into 
the cytosol and nucleus of live cells. To study the scope of 
this synthetic fusion system, we now were interested to 
study whether coiled-coil mediated fusion could be used to 
enhance the intracellular delivery of inorganic nanoparticles 
like MSNs. Typically, MSNs or lipid bilayer coated MSNs are 
taken up by endocytosis,[14,46,48,49] which can be detrimental 
to the cargo.
By employing coiled-coil mediated delivery, the cellular 
uptake mechanism might be shifted from endocytosis to a 
direct cytosolic entry via membrane fusion. In order to enhance 
the intracellular delivery of MSNs/cytC, the nanoparticles 
were coated with a fusogenic lipid bilayer containing 1 mol% 
CP4E4 (MSNs/cytC@CPE-LBs). To induce nanoparticle uptake 
via membrane fusion, cells were pretreated with CP4K4[29] 
and subsequently MSNs/cytC@CPE-LBs were added to the 
medium. Lipopeptides and lipid bilayer coated MSNs with or 
without CP4E4 were well tolerated by HeLa cells as no signs of 
toxicity were observed (Figure S2, Supporting Information). 
Confocal microscopy imaging revealed that the cytosol became 
fluorescent within 30 min, indicative of the efficient delivery of 
Atto488-labeled cytC inside the cytosol (Figure 3a). By contrast, 
when one or both of the lipopeptides were omitted, and thus 
coiled-coil mediated fusion cannot occur, only limited cellular 
uptake was observed (Figure S3, Supporting Information). The 
intracellular location of the MSNs upon CC mediated delivery 
was further investigated by transmission electron microscopy 
(TEM). It showed that a fraction of the MSNs was outside of the 
cell, some were entering into the cytoplasm while the majority 
already appeared inside the cytosol (Figure 3d,e).
Importantly, the MSNs appeared not to be localized in 
endosomes or lysosomes, but were found in the cytosol. From 
the TEM image it seemed that the MSNs were aggregated 
(Figure 3e). A possible explanation might be that upon the 
Adv. Healthcare Mater. 2017, 6, 1700759
Figure 2. Characterization of MSNs/cytC. a) Loading capacity and zeta-potential of MSNs/cytC, with different initial cytC concentrations (0.5–4 mg mL−1, 
1 × 10−3 m phosphate buffer (PB), pH 7.4). b) Dynamic light scattering (DLS) of MSNs and MSNs/cytC@CPE-LBs (1 × 10−3 m PB, pH 7.4). c) Zeta-potential 
of MSNs, MSNs/cytC, CPE-LBs, and MSNs/cytC@CPE-LBs (error bars represented zeta deviation, 1 × 10−3 m PB, pH 7.4). d) In vitro release profiles of 
MSNs and MSNs/cytC@CPE-LBs in phosphate buffered saline (PBS), pH 7.4. Error bars show the standard deviation of three independent experiments.
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delivery into the cells, the MSNs lose their lipid bilayers and 
it is well-known that bare MSNs have a tendency to aggregate. 
In comparison, the uptake efficiency of bare MSNs into cells 
is low (Figure S3c, Supporting Information). More importantly, 
in the control experiment bare MSNs were located in early 
endosomal compartments as evidenced by the presence of a 
membrane bilayer (Figure S4, Supporting Information). These 
results show that CC driven membrane fusion enhances the 
cellular uptake of these nanoparticles.
2.3. Endocytosis and Micropinocytosis Inhibitors Marginally 
Affect Delivery
To investigate the cellular uptake pathway, we repeated the 
lipid bilayer coated MSNs delivery in the presence of sev-
eral well-known inhibitors using flow cytometry measure-
ments (FACS) and confocal microscopy imaging.[27,50–54] In 
this study, wortmannin (Wor) was used as a micropinocy-
tosis inhibitor as it blocks PI3-kinase,[50,52,55,56] while gen-
istein (Gen) inhibits tyrosine-phosphorylation of Cav 1 and 
caveolin-dependent endocytosis.[57–59] Furthermore, chlor-
promazine (Chl) was used as it blocks clathrin-dependent 
endocytosis,[51,60,61] and microtubule formation was inhibited 
by nocodazole (Noc). Uptake studies in the presence of these 
inhibitors give insight in the intracellular trafficking and 
internalization mechanisms involved in the uptake of the lipid 
bilayer coated MSNs.[50–54] Finally, as endocytosis of nanopar-
ticles is an energy-dependent process, sodium azide (NaN3) 
was used to deplete the energy demands for endocytosis and 
restrict metabolic activity.[62,63]
FACS analysis revealed that Gen, Wor, and Noc had no 
adverse effect on the delivery of fluorescently labeled cytC 
(Figure 4a), whereas in the presence of Chl and NaN3, uptake 
of nanoparticles containing cytC was slightly lowered to 90% as 
compared to the initial experiment in the absence of inhibitors. 
To further study the role of CC formation on the mechanism 
of cellular uptake, we omitted the CP4K4 pretreatment of HeLa 
cells in control experiments. Without inhibitors, the MSNs/
cytC uptake was less than 60% (Figure 4b, red column). In 
the presence of Chl or NaN3, the uptake of lipid bilayer coated 
MSNs was sharply reduced to 10% (Figure 4b, dark blue and 
blue columns). This clearly indicates that in this control experi-
ment the nanoparticles are most likely taken up by a clathrin-
dependent endocytosis pathway. Taken together these inhibi-
tion studies strongly indicated that the dominant pathway for 
CC mediated MSN delivery is most likely via membrane fusion 
between the lipid bilayer coated MSNs and the cell membrane. 
By contrast, when CC mediated delivery cannot occur due to 
the absence of the lipopeptides, the dominant and less efficient 
route of cellular uptake is via endocytosis.
2.4. Cell Apoptosis Induced by cytC after Delivery
It is well-known that an increase in cytC concentration in the 
cytosol triggers caspase activation,[64–66] ultimately resulting in 
apoptosis of the cell.[39,67] Therefore, the amount of apoptosis as 
quantified by caspase activity can be used as a tool to confirm 
the actual delivery of cytC in the cytosol of cells. 100% apoptosis 
was induced by treatment with anti-Fas receptor antibody after 
5 h. CC mediated delivery and bioactivity of cytC using lipid 
Adv. Healthcare Mater. 2017, 6, 1700759
Figure 3. Intracellular delivery of cytC by MSNs@CPE-LBs. Confocal images showing a) location of Atto488 labeled cytC, b) cell nuclei stained by 
Hoechst, and e) overlay, scale bar = 25 µm. Intracellular uptake in the presence of inhibitors. c) CC mediated cellular uptake of fluorescently labeled 
cytC in CP4K4 pretreated HeLa cells. TEM images of d) delivered MSNs/cytC@CPE-LBs into CP4K4 pretreated HeLa cells. e) MSNs/cytC.
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bilayer-coated MSNs resulted in 55% of apoptosis after 48 h 
(Figure 5a, green column). By contrast, free cytC induced only 
10% of apoptosis (Figure 5a, red column), without CC infor-
mation cytC delivered by lipid bilayers induced around 20% of 
apoptosis (Figure 5d, blue column). Optical microscopy imaging 
demonstrated the morphological changes of apoptotic HeLa 
cells versus healthy cells upon cytC delivery, supporting the 
caspase assay (Figure 5b,c). In summary, coiled-coil mediated 
membrane fusion enhanced the observed 
level of apoptosis, due to the increased uptake 
and release of cytC into the cytosol of cells. In 
control experiments where one or both of the 
lipopeptides were omitted only minimal levels 
of apoptosis (<10%) were observed, revealing 
that coiled-coil mediated delivery of MSNs@
LBs is more efficient when compared to 
delivery via endocytic pathways (Figure 5d–f).
3. Conclusions
Direct cytosolic delivery of cytC encapsu-
lated MSNs decorated with a fusogenic lipid 
bilayer was achieved by targeted coiled-coil 
mediated membrane fusion with the cells 
while the uptake via endocytosis was mini-
mized as shown by the inhibition cell uptake 
study. The uptake pathway and localization of 
MSNs/cytC in HeLa cells were confirmed by 
TEM and confocal imaging, and the release 
of functional cytC was demonstrated by its 
ability to trigger enhanced levels of apop-
tosis. We believe that our coiled-coil-based 
membrane fusion system is suitable for the 
delivery of a wide range of proteins or high 
molecular weight compounds as long as 
these can be encapsulated in the pores of the 
MSNs. It is envisaged that this method is also 
suitable for the delivery of any (in)organic 
nanoparticles as long as it can be encapsu-
lated in or decorated with a fusogenic lipid 
bilayer carrying the coiled coil peptide at its 
interface. Therefore, this method of delivery 
may have applications in the field of biomedi-
cine and diagnostics.
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Figure 4. Mechanistic cellular uptake study. Intracellular uptake of a lipid bilayer coated MSNs (MSNs@CPE-LBs) in the presence of endocytosis/
micropinocytosis inhibitors. a) Coiled-coil induced lipid bilayer coated MSNs delivery and b) control experiment in which CP4K4 was omitted. Uptake 
of MSNs@CPE-LBs was studied in the absence (red bar) and presence of endocytosis inhibitors. Error bars show the standard deviation of three 
independent experiments.
Figure 5. Cytoplasmic cytC delivery induces apoptosis. a,d) Percentage of apoptotic cells as 
measured by caspase activity, after 30 and 48 h. Image of HeLa cells b) treated with cytC and 
c) MSNs@CPE-LBs where CC formation triggered apoptosis. e) CP4K4 pretreated cells incu-
bated with MSNs/cytC@LBs. f) HeLa cells incubated with MSNs/cytC@CPE-LBs after 30 h 
treatment. Apoptotic cells are rarely seen in (e) and (f). Caspase activity was determined after 
30 and 48 h. Error bars are standard deviation of three independent experiments. Error bars 
show the standard deviation of three independent experiments. Scale bar = 25 µm.
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